Pharmaceutical giant GlaxoSmithKline PLC (GSK.LN) said Monday it’s selling its thrombosis brands, together with the Notre-Dame de Bondeville manufacturing site, to Aspen Pharmacare Holdings Ltd. (APN.JO) for 0.7 billion pounds ($1.13 billion). The sale of the brands--Arixtra(R) and Fraxiparine(R)--are part of Glaxo’s plan to focus on its higher growth potential drugs and to deliver on its late-stage pipeline. Glaxo said it will use the money raised for general corporate purposes, adding that the net profit on disposal will be excluded from core operating profit and core earnings per share in 2013.
Help employers find you! Check out all the jobs and post your resume.
